Recent findings highlight significant gaps in the clinical management of metastatic castration-resistant prostate cancer (mCRPC). These gaps include the insufficient uptake of germline and somatic testing for homologous recombination repair (HRR) mutations, delays in HRR testing, and the delayed initiation of PARP inhibitor therapy.
A comprehensive real-world analysis presented at the 2025 Genitourinary Cancers Symposium underscores these issues. According to the study, 81% of the 1,022 patients analyzed did not receive HRR testing at their diagnosis. Additionally, only 35% of patients who tested positive for HRR mutations were treated with PARP inhibitors before the third line of therapy. These findings indicate a critical need for improvement in clinical practice.
“This analysis confirms gaps in the clinical management of mCRPC, particularly in the use of biomarker testing and PARP therapy,” noted the researchers. They suggested that continuing education and standardized testing practices could address these shortcomings.
Testing for HRR Mutations
The analysis included 650 patients who underwent HRR mutation testing, which encompassed germline testing, somatic testing, or a combination of both. Specifically, 21.2% of patients underwent germline testing, 58.8% underwent somatic testing, and 3.4% underwent both types of testing. Among these, 16.6% had unknown testing results.
Regarding the timing of testing, 19% of patients received testing at diagnosis, while 41% were tested during or after the first line of treatment. Another 22% underwent testing during or after the second line of therapy, and 18% were tested after receiving three or more lines of treatment. Nine percent experienced testing failures, with 38% of failures occurring in somatic tissue testing.
The analysis revealed that 38% of patients tested positive for HRR mutations, with nearly 60% of these individuals being treated with a PARP inhibitor. Following more than one line of therapy, 13 patients received PARP inhibitors, and 23% of patients were treated with a combination of PARP inhibitors and next-generation hormonal agents. Notably, 65% of those treated with PARP inhibitors received them after more than three lines of therapy.
In the group of patients treated with PARP inhibitors, specific HRR mutation-positive genes were identified, including ATM (30.9%), BRCA2 (33.6%), and CDK12 and CHEK2 (6.6% and 13.2%, respectively). Additionally, genes such as RAD54L, PALB2, and CHEK1, BRIP1, or RAD51B were found in a smaller proportion of patients.
Broader Implications
Among the 94 patients who did not receive PARP inhibitors, 15.9% were BRCA2 positive, 29% were ATM positive, and 3.7% were BRCA1 positive. The researchers emphasized the importance of identifying and treating all BRCA1/2- and ATM-positive patients with PARP inhibitors.
The expansion of this analysis aimed to determine the optimal timing for HRR mutation testing in relation to the initiation of various therapies. The study focused on evaluating when novel hormonal therapies and PARP inhibitors were introduced in HRR mutation-positive patients.
For this current analysis, researchers utilized the IntegraConnect – Precision Q deidentified database, which compiled electronic health and practice management data from 500 U.S. care sites. Medical curators manually reviewed patient charts to extract critical data, including the success rate and results of testing, timing and frequency of germline and somatic testing for HRR mutations, and the lines of therapy in which novel hormonal therapies and/or PARP inhibitors were initiated.
Conclusion: Improving Patient Care
This study highlights significant gaps in the management of mCRPC, emphasizing the need for more timely HRR mutation testing and appropriate use of PARP inhibitors. Addressing these issues through continued education and standardized testing practices may improve clinical outcomes for patients with this aggressive form of cancer.
As researchers and clinicians work to refine their approaches, these findings underscore the critical importance of adherence to best practices in the management of metastatic castration-resistant prostate cancer.
If you or someone you know is facing mCRPC, discussing these clinical gaps with a healthcare provider can help ensure the most effective treatment plan. Stay informed and advocate for comprehensive testing and timely interventions to enhance treatment outcomes.
We encourage you to share your thoughts and experiences in the comments section below. Your insights can help raise awareness and improve patient care.
